STAMFORD, Conn., May 12, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a key opinion leader (KOL) breakfast meeting focused on CR845’s potential to treat patients with chronic kidney disease (CKD)-associated pruritus on Tuesday, May 16, 2017 from 8:30 to 10:30 a.m. ET in New York.
The meeting will feature keynote presentations from Steven Zeig, M.D., Nephrologist and Principal Investigator, Pines Clinical Research Inc., and Shayan Shirazian, M.D., Nephrologist and Clinical Researcher, Winthrop-University Hospital and Stony Brook University School of Medicine. Additionally, executives from Cara will review the data from Part A of the Phase 2/3 trial in patients with CKD-associated pruritus and provide an overview of the CR845 program.
A live audio webcast of the event and accompanying slides can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara Therapeutics is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.